Risk Factors for Fat Necrosis After Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer in a Phase 1 Clinical Trial.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 11 2020
Historique:
received: 24 03 2020
revised: 17 05 2020
accepted: 18 05 2020
pubmed: 29 5 2020
medline: 10 4 2021
entrez: 29 5 2020
Statut: ppublish

Résumé

This study reports predictive dosimetric and physiologic factors for fat necrosis after stereotactic-partial breast irradiation (S-PBI). Seventy-five patients with ductal carcinoma-in situ or invasive nonlobular epithelial histologies stage 0, I, or II, with tumor size <3 cm were enrolled in a dose-escalation, phase I S-PBI trial between January 2011 and July 2015. Fat necrosis was evaluated clinically at each follow-up. Treatment data were extracted from the Multiplan Treatment Planning System (Cyberknife, Accuray). Univariate and stepwise logistic regression analyses were conducted to identify factors associated with palpable fat necrosis. With a median follow-up of 61 months (range: 4.3-99.5 months), 11 patients experienced palpable fat necrosis, 5 cases of which were painful. The median time to development of fat necrosis was 12.7 months (range, 3-42 months). On univariate analyses, higher V32.5-47.5 Gy (P < .05) and larger breast volume (P < .01) were predictive of any fat necrosis; higher V35-50 Gy (P < .05), receiving 2 treatments on consecutive days (P = .02), and higher Dmax (P = .01) were predictive of painful fat necrosis. On multivariate analyses, breast volume larger than 1063 cm Early-stage breast cancer patients treated with breast conserving surgery and S-PBI in our study had a fat necrosis rate comparable to other accelerated partial breast irradiation modalities, but S-PBI is less invasive. To reduce risk of painful fat necrosis, we recommend not delivering fractions on consecutive days; limiting V42.5 < 50 cm

Identifiants

pubmed: 32464155
pii: S0360-3016(20)31149-4
doi: 10.1016/j.ijrobp.2020.05.025
pii:
doi:

Types de publication

Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

697-706

Informations de copyright

Published by Elsevier Inc.

Auteurs

Asal Rahimi (A)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: Asal.Rahimi@utsouthwestern.edu.

Yuanyuan Zhang (Y)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Dong W Kim (DW)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Howard Morgan (H)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Ferzana Hossain (F)

Medical School, University of Texas Southwestern Medical Center, Dallas, Texas.

Marilyn Leitch (M)

Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.

Rachel Wooldridge (R)

Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.

Stephen Seiler (S)

Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas.

Sally Goudreau (S)

Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas.

Barbara Haley (B)

Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.

Roshni Rao (R)

Department of Surgery, Columbia University, New York, New York.

Aeisha Rivers (A)

Department of Surgery, Memorial Health care System, Miramar, Florida.

Ann Spangler (A)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Chul Ahn (C)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Stella Stevenson (S)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Jason Staley (J)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Kevin Albuquerque (K)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Chuxiong Ding (C)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Xuejun Gu (X)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Bo Zhao (B)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Robert Timmerman (R)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH